Diabetes Is Not For The Faint Of Heart
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.
You may also be interested in...
Merck And Pfizer Make A Late Play For The Diabetes Market
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
In A Changing Diabetes Drug Market, Who Will Come Out On Top?
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.
US FDA Announces Update To Recognized Standards List
The national and international standards can be used during the device assessment process.